Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based study
- PMID: 21499808
- DOI: 10.1245/s10434-011-1715-2
Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based study
Abstract
Purpose: To test whether the rates of in-hospital mortality, complications, and transfusions are higher in patients treated with cytoreductive nephrectomy (CNT) for metastatic renal cell carcinoma (mRCC) relative to patients treated with nephrectomy (NT) for non-mRCC.
Methods: We assessed 17,688 patients treated with a NT between years 1999 and 2008, within the Florida Inpatient Database. Chi-square and Student t-tests were used to compare the statistical significance of differences in proportions and means, respectively. Univariable and multivariable logistic regression analyses tested the relationship between surgery type (CNT vs. NT) and three end points: in-hospital mortality, complications, and transfusions.
Results: Overall, 6.0% of patients underwent CNT. The rates of in-hospital mortality, complications, and transfusions were 2.4, 26.5, and 24.3% in CNT patients versus 0.9, 18.9, and 11.1% in NT patients. At multivariable analyses, CNT patients demonstrated a 2.0-, 1.3-, and 2.4-fold higher risk of in-hospital mortality, complications, and transfusions (all P < 0.001). Similarly, more advanced age, comorbidity, and the cumulative number of secondary surgical procedures were independent predictors of a higher risk of in-hospital mortality, complications, and transfusions (all P < 0.001).
Conclusions: The rate of in-hospital mortality, complications, and transfusions is higher in patients treated with CNT relative to NT. Older age, higher comorbidity, and the necessity of secondary surgical procedures further increases the risk of all aforementioned end points. Physicians should consider these observations during the planning of a CNT, and patients should be informed accordingly.
Similar articles
-
Higher perioperative morbidity and in-hospital mortality in patients with end-stage renal disease undergoing nephrectomy for non-metastatic kidney cancer: a population-based analysis.BJU Int. 2012 Sep;110(6 Pt B):E183-90. doi: 10.1111/j.1464-410X.2012.10936.x. Epub 2012 Feb 9. BJU Int. 2012. PMID: 22321256
-
Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma.Urology. 2009 Feb;73(2):342-6. doi: 10.1016/j.urology.2008.09.022. Epub 2008 Nov 28. Urology. 2009. PMID: 19041122
-
Cytoreductive nephrectomy in the elderly: a population-based cohort from the USA.BJU Int. 2012 Jun;109(12):1807-12. doi: 10.1111/j.1464-410X.2011.10569.x. Epub 2011 Sep 27. BJU Int. 2012. PMID: 21951647
-
[When is cytoreductive nephrectomy not beneficial for patients with metastatic renal cell carcinoma?].Urologe A. 2017 May;56(5):610-616. doi: 10.1007/s00120-017-0363-y. Urologe A. 2017. PMID: 28314968 Review. German.
-
Renal cell carcinomas in patients on long-term hemodialysis.Contrib Nephrol. 1999;128:28-44. doi: 10.1159/000059977. Contrib Nephrol. 1999. PMID: 10597375 Review. No abstract available.
Cited by
-
Management of Metastatic Renal Cell Carcinoma in a Tertiary Care Hospital.Cureus. 2023 Feb 28;15(2):e35623. doi: 10.7759/cureus.35623. eCollection 2023 Feb. Cureus. 2023. PMID: 37007390 Free PMC article.
-
The impact of cytoreductive nephrectomy on survival outcomes in patients with metastatic renal cell carcinoma receiving immunotherapy: An evidence-based analysis of comparative outcomes.Front Immunol. 2023 Mar 14;14:1132466. doi: 10.3389/fimmu.2023.1132466. eCollection 2023. Front Immunol. 2023. PMID: 36999026 Free PMC article.
-
Do Metastatic Kidney Cancer Patients Benefit From Cytoreductive Nephrectomy? A Real-World Retrospective Study From the SEER Database.Front Surg. 2021 Aug 30;8:716455. doi: 10.3389/fsurg.2021.716455. eCollection 2021. Front Surg. 2021. PMID: 34557516 Free PMC article.
-
Long-Term Survival Outcomes of Cytoreductive Nephrectomy Combined with Targeted Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-Analysis.Cancers (Basel). 2021 Feb 9;13(4):695. doi: 10.3390/cancers13040695. Cancers (Basel). 2021. PMID: 33572149 Free PMC article. Review.
-
The role of open radical nephrectomy in contemporary management of renal cell carcinoma.Transl Androl Urol. 2020 Dec;9(6):3123-3139. doi: 10.21037/tau-19-327. Transl Androl Urol. 2020. PMID: 33457285 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
